Skip to content

An evaluation of a new contact lens design against two prototype designs and a commercially-available single vision design

Prospective, double-masked, bilateral wear, crossover, dispensing clinical trial to compare the visual performance between a new commercially-available contact lens design which utilise digital zone optics, prototype contact lens designs which utilise higher-order spherical aberrations to increase depth-of-focus and a commercially-available single vision contact lens

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617000819325
Acronym
The DZO Trial
Enrollment
35
Registered
2017-06-05
Start date
2017-11-20
Completion date
2018-03-15
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to compare the visual performance (defined by visual acuity measurements and subjective ratings0 between a new commercially-available contact lens design which utilise digital zone optics (DZO), two prototype Extended Depth-of-Focus (EDOF) contact lens designs which utilise higher-order spherical aberration terms and a commercially-available single vision contact lens (SV). To achieve this, participants will wear each of the 4 lens designs for a minimum of 5 days. Outcome measures will comprise visual acuity and subjective ratings. Our hypotheses are there will be no difference between lens designs for either visual acuity or subjective ratings.

Interventions

This trial will be a prospective, bilateral, randomised, double-masked, cross-over clinical trial. Participants will wear four lens types for 5 consecutive days on a single-use, daily wear basis with a minimum two day wash-out between lens types. The four lens types comprise: Commercially-available single vision lenses made from comfilcon A: Base curve = 8.6 mm, Diameter = 14 mm, Power Range = -0.75 to -6.00 D Commercially-available lenses utilizing digital zone optics made from comfilcon A: Bas

This trial will be a prospective, bilateral, randomised, double-masked, cross-over clinical trial. Participants will wear four lens types for 5 consecutive days on a single-use, daily wear basis with a minimum two day wash-out between lens types. The four lens types comprise: Commercially-available single vision lenses made from comfilcon A: Base curve = 8.6 mm, Diameter = 14 mm, Power Range = -0.75 to -6.00 D Commercially-available lenses utilizing digital zone optics made from comfilcon A: Base curve = 8.6 mm, Diameter = 14 mm, Power Range = -0.75 to -6.00 D Two prototype extended depth of focus (EDOF) which utilize deliberate manipulation of multiple higher-order spherical aberrations terms to extend depth of focus made from Poly-HEMA material. Base curve = 8.4 mm, Diameter = 14 mm, Power Range = -0.75 to -6.00 D Minimum wearing time will be 5 days and 6 hours/day with no maximum wearing time provided lenses are not slept in overnight. There will 9 visits comprising Baseline and two visits for each of the 4 lens designs (Fitting and Assessment). Each visit will be approximately 45 minutes in duration. Baseline visits will comprise auto-refraction, subjective refraction with visual acuity measurement and ocular assessment with a slit-lamp biomicroscope (a specialized microscope for viewing the eye). Fitting visits will be performed by unmasked investigators and comprise contact lens fitting, assessment of contact lens visual acuity and assessment of contact lenses on eye with a slit-lamp biomicroscope (a specialized microscope for viewing the eye). Assessment visits will be performed by masked investigators and comprise assessment of contact lens visual acuity, distance and near heterophoria, monocular accommodative facility and subjective ratings of vision questionnaire utilizing a 1-10 numeric rating scale, and the validated Computer Vision syndrome Questionnaire. In between Fitting and Assessment visits, participants will complete a subjective ratings of vision take-home questionnaire utilizing a 1-10 numeric rating scale. A minimum 2-day wash-out will be observed between Fitting and Assessment visits where study lenses are not worn. Participants will wear their habitual vision correction in between wearing study lenses All contact lenses will be prescribed and all assessments will be carried out by an optometrist. Participants will be instructed to return all unused contact lenses.

Sponsors

Brien Holden Vision Institute
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent. Be between 18-40 years old, male or female. Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator. Have ocular health findings considered to be “normal” and which would not prevent the participant from safely wearing contact lenses. Is myopic and correctable to at least 6/12 (20/40) or better in each eye with contact lenses. Be suitable and willing to wear contact lenses.

Exclusion criteria

Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses. Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial. Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. NB: Systemic antihistamines are allowed on an “as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used. Eye surgery within 12 weeks immediately prior to enrolment for this trial. Previous corneal refractive surgery. Contraindications to contact lens wear. Known allergy or intolerance to ingredients in any of the clinical trial products. Currently enrolled in another clinical trial. Pregnancy*. The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant’s best interests. *Formal testing of pregnancy is not required. A participant’s verbal report is sufficient.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026